Silence Therapeutics PLC (SLN)

Silence Therapeutics PLC (SLN) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $613M; returns 1 day +0.1%, 1 week +126.6%, 1 year +171.3%.

Silence Therapeutics PLC, founded in 1994 and headquartered in London, is a global clinical-stage biotechnology company focused on developing novel siRNA (short interfering RNA) therapeutics. They leverage their proprietary mRNAi GOLD™ platform to create siRNAs that precisely target and silence disease-associated genes, primarily in the liver.

Groups SLN belongs to

• Biotechnology
• United Kingdom Companies
• Biopharmaceutical
• Clinical Stage Biotech
• Life Sciences
• Rare Diseases
• Cardiovascular Therapies
• Hematology
• Healthcare
• Precision Medicine

SLN financial model: income statement, cash flow and balance sheet